GR3033290T3 - Arylazo chromoionophores. - Google Patents

Arylazo chromoionophores.

Info

Publication number: GR3033290T3
Authority: GR; Greece
Prior art keywords: monoclonal antibody; egf; tumor cells; inhibiting; producing
Prior art date: 1992-08-18

Application number

GR20000400972T

Other languages

English (en)

Inventor

Ordonez Alicia Calle Fernandez

De Acosta Del Rio Cristi Mateo

Abraham Amparo Emilia C Macias

Perez Pedro Pablo Macineira

Bravo Blanca Rosa Tormo

Rodriguez Rolando Perez

Original Assignee

Ct De Immunologia Molecular

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-18

Filing date

2000-04-20

Publication date

2000-09-29

1992-08-18 Priority claimed from CU1992100A external-priority patent/CU22387A1/es

2000-04-20 Application filed by Ct De Immunologia Molecular filed Critical Ct De Immunologia Molecular

2000-09-29 Publication of GR3033290T3 publication Critical patent/GR3033290T3/el

Links

102000009024 Epidermal Growth Factor Human genes 0.000 abstract 4
101800003838 Epidermal growth factor Proteins 0.000 abstract 4
229940116977 epidermal growth factor Drugs 0.000 abstract 4
230000002401 inhibitory effect Effects 0.000 abstract 4
210000004881 tumor cell Anatomy 0.000 abstract 3
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 3
239000012634 fragment Substances 0.000 abstract 2
230000035755 proliferation Effects 0.000 abstract 2
230000002195 synergetic effect Effects 0.000 abstract 2
101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
230000000295 complement effect Effects 0.000 abstract 1
230000001472 cytotoxic effect Effects 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
150000002270 gangliosides Chemical class 0.000 abstract 1
229940116978 human epidermal growth factor Drugs 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000001855 preneoplastic effect Effects 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

GR20000400972T 1992-08-18 2000-04-20 Arylazo chromoionophores. GR3033290T3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CU1992100A CU22387A1 (es)	1992-08-18	1992-08-18	Anticuerpos monoclonados que reconocen el receptor del factor de crecimiento epidermico. procedimiento de obtencion
CU1993017		1993-03-01

Publications (1)

Publication Number	Publication Date
GR3033290T3 true GR3033290T3 (en)	2000-09-29

Family

ID=25746823

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GR20000400972T GR3033290T3 (en)	1992-08-18	2000-04-20	Arylazo chromoionophores.

Country Status (7)

Country	Link
EP (1)	EP0586002B1 (el)
AT (1)	ATE188874T1 (el)
DE (1)	DE69327620T2 (el)
DK (1)	DK0586002T3 (el)
ES (1)	ES2144440T3 (el)
GR (1)	GR3033290T3 (el)
PT (1)	PT586002E (el)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CU22545A1 (es) *	1994-11-18	1999-03-31	Centro Inmunologia Molecular	Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
DE69428764T2 (de)	1993-12-24	2002-06-20	Merck Patent Gmbh	Immunokonjugate
US6149921A (en) *	1993-12-29	2000-11-21	Centro De Inmunologia Molecular	Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22420A1 (es) *	1993-12-29	1996-01-31	Centro Inmunologia Molecular	Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
GB9405046D0 (en) *	1994-03-15	1994-04-27	Unilever Plc	Skin treatment composition
CU22615A1 (es) *	1994-06-30	2000-02-10	Centro Inmunologia Molecular	Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
EP0706799B1 (en) *	1994-09-16	2001-11-14	MERCK PATENT GmbH	Immunoconjugates II
IT1277827B1 (it) *	1995-03-01	1997-11-12	Ministero Uni Ricerca Scient E	Anticorpo monoclonale chimerico murino/umano o un suo frammento specifico per il recettore egf (egf-r)
EP0745612B1 (en) *	1995-05-26	2001-11-07	MERCK PATENT GmbH	Anti-idiotypic antibodies which induce an immune response against epidermal growth factor receptor
DE69616651D1 (de) *	1995-05-26	2001-12-13	Merck Patent Gmbh	Antiidiotypische Antikörper die eine Immunantwort gegen den Rezeptor für epidermalen Wachstumsfaktor induzieren
US5942602A (en) *	1997-02-13	1999-08-24	Schering Aktiengessellschaft	Growth factor receptor antibodies
US6235883B1 (en) *	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en)	1997-05-05	2002-11-21	Aya Jakobovits	Human monoclonal antibodies to epidermal growth factor receptor
EP1278851B1 (en) *	2000-05-19	2006-01-18	Scancell Limited	Humanised antibodies to the epidermal growth factor receptor
CU22979A1 (es) *	2000-12-08	2004-09-09	Centro Inmunologia Molecular	Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US7829084B2 (en)	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
AU2002241922B2 (en) *	2001-01-17	2007-10-25	Aptevo Research And Development Llc	Binding domain-immunoglobulin fusion proteins
CU23007A1 (es) *	2001-04-06	2004-12-17	Ct De Inmunologia Molecular Ct De Inmunologia Mole	Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
ATE446317T1 (de)	2001-05-11	2009-11-15	Ludwig Inst For Cancer Res Ltd	Spezifische bindungsproteine und ihre verwendung
US20100056762A1 (en)	2001-05-11	2010-03-04	Old Lloyd J	Specific binding proteins and uses thereof
CA2450285C (en)	2001-06-13	2016-08-02	Genmab A/S	Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US7595378B2 (en)	2001-06-13	2009-09-29	Genmab A/S	Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7696320B2 (en)	2004-08-24	2010-04-13	Domantis Limited	Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US7754209B2 (en)	2003-07-26	2010-07-13	Trubion Pharmaceuticals	Binding constructs and methods for use thereof
DE10355904A1 (de)	2003-11-29	2005-06-30	Merck Patent Gmbh	Feste Formen von anti-EGFR-Antikörpern
PT1912675E (pt)	2005-07-25	2014-05-09	Emergent Product Dev Seattle	Moléculas de ligaçao especificas para cd37 e especificas para cd20
WO2007146968A2 (en)	2006-06-12	2007-12-21	Trubion Pharmaceuticals, Inc.	Single-chain multivalent binding proteins with effector function
US9090693B2 (en)	2007-01-25	2015-07-28	Dana-Farber Cancer Institute	Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
ES2542152T3 (es)	2007-03-15	2015-07-31	Ludwig Institute For Cancer Research Ltd.	Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas
JP5532486B2 (ja)	2007-08-14	2014-06-25	ルードヴィッヒインスティテュートフォーキャンサーリサーチ	Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途
CN102099377A (zh)	2008-04-11	2011-06-15	新兴产品开发西雅图有限公司	Cd37免疫治疗剂及其与双功能化学治疗剂的联合
EP2385955B1 (en)	2009-01-12	2020-08-12	CytomX Therapeutics, Inc.	Modified antibody compositions, methods of making and using thereof
CU24070B1 (es) *	2011-12-27	2015-01-29	Ct De Inmunología Molecular	Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
KR102329024B1 (ko)	2013-12-23	2021-11-19	바이엘 파마 악티엔게젤샤프트	키네신 스핀들 단백질(ksp)과의 항체 약물 접합체 (adcs)
US10329348B2 (en)	2014-10-23	2019-06-25	Innate Pharma	Treatment of cancers using anti-NKG2A agents
JP6971858B2 (ja)	2015-06-22	2021-11-24	バイエルファーマアクチエンゲゼルシャフト	酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ）
AU2016282724A1 (en)	2015-06-23	2018-01-18	Bayer Pharma Aktiengesellschaft	Targeted conjugates of KSP inhibitors
MY188446A (en)	2015-07-27	2021-12-09	Innocimab Pte Ltd	Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr)
WO2017053469A2 (en)	2015-09-21	2017-03-30	Aptevo Research And Development Llc	Cd3 binding polypeptides
WO2017060322A2 (en)	2015-10-10	2017-04-13	Bayer Pharma Aktiengesellschaft	Ptefb-inhibitor-adc
EP3919518A1 (en)	2016-06-15	2021-12-08	Bayer Pharma Aktiengesellschaft	Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
IL291308B2 (en)	2016-12-21	2024-07-01	Bayer Pharma AG	Antibody drug conjugates (adcs) having enzymatically cleavable groups
CN110072556B (zh)	2016-12-21	2023-05-02	拜耳制药股份公司	具有ksp抑制剂的特异性抗体药物缀合物(adc)
CA3122191A1 (en)	2018-12-26	2020-07-02	Innate Pharma	Compounds and methods for treatment of head and neck cancer

1993
- 1993-08-18 DK DK93202428T patent/DK0586002T3/da not_active Application Discontinuation
- 1993-08-18 PT PT93202428T patent/PT586002E/pt unknown
- 1993-08-18 DE DE69327620T patent/DE69327620T2/de not_active Expired - Lifetime
- 1993-08-18 ES ES93202428T patent/ES2144440T3/es not_active Expired - Lifetime
- 1993-08-18 EP EP93202428A patent/EP0586002B1/en not_active Expired - Lifetime
- 1993-08-18 AT AT93202428T patent/ATE188874T1/de active
2000
- 2000-04-20 GR GR20000400972T patent/GR3033290T3/el unknown

Also Published As

Publication number	Publication date
DK0586002T3 (da)	2000-06-19
DE69327620D1 (de)	2000-02-24
EP0586002B1 (en)	2000-01-19
PT586002E (pt)	2000-07-31
EP0586002A2 (en)	1994-03-09
ES2144440T3 (es)	2000-06-16
EP0586002A3 (en)	1994-05-25
DE69327620T2 (de)	2000-08-03
ATE188874T1 (de)	2000-02-15

Publication	Publication Date	Title
GR3033290T3 (en)	2000-09-29	Arylazo chromoionophores.
NZ210867A (en)	1989-01-06	Tumour-specific monoclonal antibodies, production thereof and use
PL311661A1 (en)	1996-03-04	Single-chain anti-egfr fv and anti-egfr antibodies
WO1997019111A3 (es)	1998-02-12	Anticuerpos monoclonales anti-cd6 y sus utilizaciones
WO2001005425A3 (en)	2001-05-17	Combined preparations comprising daunorubicin derivatives and her2 antibodies
HUP0101160A2 (hu)	2001-08-28	Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására
AU2190997A (en)	1997-09-10	Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation
GR3036375T3 (en)	2001-11-30	Monoclonal and chimeric antibodies specific for human tumor necrosis factor.
MX9708008A (es)	1998-03-31	Anticuerpos monoclonales contra vih-1 y vacunas hechas de los mismos.
EP0220858A3 (en)	1988-08-03	Monoclonal anti-human breast cancer antibodies, corresponding hybridomas, the production and use thereof
CA2401604A1 (en)	2001-09-07	Method of treating cancer with anti-neurotrophin agents
MX9705349A (es)	1998-07-31	Anticuerpo monoclonal 1a7 y su uso para el tratamiento de melanona y carcinoma de celulas pequeñas.
MY137078A (en)	2008-12-31	Recombinant antibodies associated to gangliosides. their use indiagnosis and treatment of tumors.
WO1996022373A3 (en)	1996-10-03	Monoclonal antibody 1a7 and use for the treatment of melanoma and small cell carcinoma
NZ237688A (en)	1993-01-27	Antibody-cytotoxic immunoconjugate-containing compositions and cancer treatment
EP0198086A4 (en)	1987-03-09	MAN-MOUSE HYBRIDOMA PRODUCING HUMAN ANTIVIRAL ANTIBODY, PREPARATION METHOD AND HUMAN ANTIVIRAL MONOCLONAL ANTIBODY.
EP0341684A3 (en)	1990-01-17	Human monoclonal antibody, hybridoma producing the same and pharmaceutical
EP0166458A3 (en)	1988-05-18	Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells
EP0526888A3 (en)	1993-09-01	Monoclonal antibody reactive with human pancreas cancer tissue
LTIP1867A (en)	1995-08-25	Hybridoma producing murine monoclonal antibodies against human growth hormone
CS616789A1 (en)	1990-12-13	Murine lymphocyte hybridoma img-czas h-12h8 producing monoclonal immunoglobulin against human choriogonadotropic hormone
BG49665A1 (en)	1992-01-15	Hybridom cell line, secreting monoclonal antibody against determinant 05 salmonelli of group b
CS616989A1 (en)	1990-12-13	Murine lymphocyte hybridoma img-czas h-14h2 producing monoclonal immunoglobulin against human choriogonadotropic hormone
CS617089A1 (en)	1990-12-13	Murine lymphocyte hybridoma img-czas h-9f9 producing monoclonal immunoglobulin against human choriogonadotropic hormone
CS347190A3 (en)	1992-01-15	Murine lymphocyte hybridoma tsh-116 producing monoclonal antibody of the class igg 2a against human thyrostimulative hormone